Diabetes Research and Clinical Practice
Volume 90, Issue 2 , Pages e25-e26 , November 2010

Angiotensin converting enzyme inhibitor or angiotensin II receptor blocker for the prevention of type 2 diabetes mellitus?

  • Ching-Chu Chen

      Affiliations

    • Division of Endocrinology and Metabolism, Department of Medicine, China Medical University Hospital, Taichung, Taiwan
    • School of Chinese Medicine, College of Chinese Medicine, China Medical University, Taichung, Taiwan
    • Corresponding Author InformationCorresponding author at: Division of Endocrinology and Metabolism, Department of Medicine, China Medical University Hospital, No. 2, Yuh-Der Road, Taichung 40447, Taiwan. Tel.: +886 4 22062121x3489; fax: +886 4 22038883.

Received 8 January 2010

References 

  1. Scheen AJ. Prevention of type 2 diabetes mellitus through inhibition of the rennin–angiotensin system. Drugs. 2004;64:2537–2565
  2. The DREAM Trial Investigators. Effect of ramipril on the incidence of diabetes. N Engl J Med. 2006;355:1551–1562
  3. The NAVIGATOR Study Group. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010;
  4. Chen CC, Hsiang CY, Chiang AN, Lo HY, Li CI. Peroxisome proliferator-activated receptor gamma transactivation-mediated potentiation of glucose uptake by Bai-Hu-Tang. J Ethnopharmacol. 2008;118:46–50

PII: S0168-8227(10)00277-9

doi: 10.1016/j.diabres.2010.05.028

Diabetes Research and Clinical Practice
Volume 90, Issue 2 , Pages e25-e26 , November 2010

Article Tools

* Image Usage & Resolution